Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL711950 | 0.95 | CYP3A4 (0.39) | MAOBMCL1 | |
| Trifluoroacetic Acid SCHEMBL708957 | 0.93 | MAOB (0.36) | MAOBCTSLCTSSCTSKGPR132 | |
| SCHEMBL10206664 | 0.91 | PDE2A (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL709893 | 0.90 | PDE4A (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL711513 | 0.88 | SMO (0.41) | MAOBGPR132DHODHPPARG | |
| Trifluoroacetic Acid SCHEMBL711385 | 0.88 | CYP3A4 (0.39) | MAOBGPR132MCL1 | |
| Trifluoroacetic Acid SCHEMBL709562 | 0.87 | SMO (0.40) | MAOBPPARG | |
| SCHEMBL9071894 | 0.87 | CYP3A4 (0.46) | MAOBALOX5MCL1 | |
| Trifluoroacetic Acid SCHEMBL711107 | 0.86 | GPR132 (0.43) | GPR132DHODHPPARGALOX5PSEN1 | |
| Trifluoroacetic Acid SCHEMBL711971 | 0.86 | CYP3A4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | MAOB 1046/4885CTSL 1247/4885CTSS 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.